PHK
BOLT icon

Point72 Hong Kong’s Bolt Biotherapeutics BOLT Stock Holding History

Point72 Hong Kong’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-105
Closed -$26K – 1916
2021
Q3 		$26K Buy
+105
New +$29.7K ﹤0.01% 1648

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Point72 Hong Kong's BOLT Position: Q4 2021 in Review

Point72 Hong Kong sold out of Bolt Biotherapeutics (BOLT) in Q4 2021, closing a stake of 105 shares — an estimated $26K sold.

Point72 Hong Kong first reported a position in BOLT in Q3 2021 and held it in 1 quarter. The position peaked at $26K in Q3 2021. 62 funds tracked by Wall St. Rank hold BOLT as of Q4 2021.

  • Point72 Hong Kong reported no remaining Bolt Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Point72 Hong Kong sold 105 Bolt Biotherapeutics shares in Q4 2021, an estimated $26K.
  • Point72 Hong Kong first reported a position in Bolt Biotherapeutics in Q3 2021 and held it in 1 quarter.
  • Point72 Hong Kong's Bolt Biotherapeutics position peaked at $26K in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2021.

Based on Point72 Hong Kong's 13F filing for Q4 2021, filed 14 Feb 2022.